MetaSight Diagnostics
MetaSight pioneers the development of accurate, affordable, and accessible disease diagnostics and monitoring through advanced blood testing, designed for high-volume population-scale screening. They utilize a robust discovery platform integrating proprietary high throughput mass-spectrometry multi-OMICs technology, population-scale serum samples collection, and electronic health records to create the world's largest blood molecular database, driving innovation in disease diagnostics and monitoring.
Industries
Nr. of Employees
small (1-50)
MetaSight Diagnostics
2 Haim Holtsman st., Rehovot, ISRAEL
Products
Blood-based assay for MASH-associated liver fibrosis (proteomics-based)
A serum proteomics-derived diagnostic and monitoring assay targeting three serum biomarkers to detect significant or advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis; intended for CLIA/LDT deployment and clinical-trial use.
Serum lipid biomarker discovery program for colorectal cancer
Discovery program identifying serum lipid biomarkers with strong association to colorectal cancer from untargeted LC-MS multi-omics screening.
Blood-based assay for MASH-associated liver fibrosis (proteomics-based)
A serum proteomics-derived diagnostic and monitoring assay targeting three serum biomarkers to detect significant or advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis; intended for CLIA/LDT deployment and clinical-trial use.
Serum lipid biomarker discovery program for colorectal cancer
Discovery program identifying serum lipid biomarkers with strong association to colorectal cancer from untargeted LC-MS multi-omics screening.
Services
Design and execution of large-scale untargeted LC-MS multi-omics screening studies with linked de-identified EHRs for biomarker discovery and signature derivation.
Design and execution of large-scale untargeted LC-MS multi-omics screening studies with linked de-identified EHRs for biomarker discovery and signature derivation.
Expertise Areas
- Mass-spectrometry based metabolomics
- Lipidomics and proteomics
- Population-scale biomarker discovery
- EHR-linked observational studies
Key Technologies
- Untargeted LC-MS metabolomics
- Targeted LC-MS assays
- High-throughput mass spectrometry
- Lipidomics
News & Updates
MetaSight Diagnostics raised $8 million in a Series A funding round in November 2024.
In July 2023, MetaSight announced a partnership with Maccabi's KSM Research and Innovation Center to conduct extensive metabolomics research.
In July 2023, Forbes featured MetaSight in an article about AI and data analysis revolutionizing healthcare.
MetaSight will present at The Liver Meeting 2024 about a blood test for monitoring liver fibrosis.
MetaSight presented at The Liver Meeting 2023 about a serum diagnostic signature for liver fibrosis.
MetaSight presented at the ASMS conference about untargeted LC-MS metabolomics screening.
MetaSight Diagnostics raised $8 million in a Series A funding round in November 2024.
In July 2023, MetaSight announced a partnership with Maccabi's KSM Research and Innovation Center to conduct extensive metabolomics research.
In July 2023, Forbes featured MetaSight in an article about AI and data analysis revolutionizing healthcare.
MetaSight will present at The Liver Meeting 2024 about a blood test for monitoring liver fibrosis.
MetaSight presented at The Liver Meeting 2023 about a serum diagnostic signature for liver fibrosis.
MetaSight presented at the ASMS conference about untargeted LC-MS metabolomics screening.